Loading ...
Sorry, an error occurred while loading the content.

References for Hepatitis C: Epidemiology and Review of Complementary/Alternative Medicine Treatments

Expand Messages
  • claudine intexas
    Hepatitis C: Epidemiology and Review of Complementary/Alternative Medicine Treatments by Lyn Patrick, ND References 1. World Health Organization. Hepatitis C:
    Message 1 of 1 , Jan 1, 2001
      Hepatitis C: Epidemiology and Review of
      Complementary/Alternative Medicine Treatments

      by Lyn Patrick, ND


      1. World Health Organization. Hepatitis C: global
      prevalence. Wkly Epidemiol Rec 1997;10:65-72.

      2. Sherlock S. Clinical features of hepatitis. In:
      Zuckerman AJ, Thomas HC, eds. Viral Hepatitis, 2nd ed.
      London: Churchill Livingston; 1998:1-13.

      3. Births and Deaths, Preliminary data for 1997. Natl
      Vital Stat Rep 1998;47:1-8. NIH Consensus Development

      4. NIH Consensus Development Conference: Management of
      Hepatitis C. April 27, 1998. National Institutes of
      Health, Bethesda, Maryland.

      5. Di Bisceglie AM, Order SE, Klein JK, et al. The
      role of chronic viral hepatitis in hepatocellular
      carcinoma in the United States. Am J Gastoenterol

      6. Lindsay KL. Therapy of hepatitis C: an overview.
      NIH Consensus Development Conference: Management of
      Hepatitis C. April 1998. National Institutes of
      Health, Bethesda, Maryland.

      7. Carithers RL. Therapy of hepatitis C: Interferon
      Alfa-2B. NIH Consensus Development Conference:
      Management of Hepatitis C. April 1998. National
      Institutes of Health, Bethesda, Maryland.

      8. Nishiguchi S, Kuroki R, Nakatani S, et al.
      Randomized trial of effects of interferon-alfa on
      incidence of hepatocellular carcinoma in chronic
      active hepatitis C with cirrhosis. Lancet

      9. McHutchinson JG, Gordon SC, Schiff ER, et al.
      Interferon alfa-2b alone or in combination with
      ribavirin as initial treatment for chronic hepatitis
      C. N Eng J Med 1998;339:1485-1492.

      10. Sherman A. HCV on the threshold. Infect Med

      11. Purcell R. The hepatitis C virus: overview. NIH
      Consensus Development Conference: Management of
      Hepatitis C. Hepatology 1997;26:11S-14S.

      12. Mozzi F, Rebulla T, Locatelli E, et al. Antibody
      to hepatitis C virus in Italian thalassemics evaluated
      with second generation tests. Proceedings of the Third
      International Symposium on Hepatitis C Virus.
      Strasbourg, France 1991:90.

      13. Locasciolli A, Gornati G, Tagger A, et al.
      Hepatitis C virus infection and chronic liver disease
      in children with leukemia in long term remission.
      Blood 1991;88:53-54.

      14. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ.
      The risk of transfusion-transmitted viral infections.
      N Engl J Med 1996;334:1685-1690.

      15. Brown D, Manolakopoulos S, Dusheiko G. Diagnosis
      of acute and chronic hepatitis C. In: Zuckerman AJ,
      Thomas HC. eds. Viral Hepatitis, 2nd ed. London:
      Churchill Livingston; 1998:319-338.

      16. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al.
      Hepatitis C virus genotypes: an investigation of
      type-specific differences in geographic origin of
      disease. Hepatology 1994;19:13-18.

      17. Yoshioka K, Kakumu S, Wakita T, et al. Detection
      of hepatitis C virus by polymerase chain reaction and
      response to interferon-alpha therapy: relationship to
      genotypes of hepatitis C virus. Hepatology

      18. McGarvey MJ, Houghton M, Weiner AJ. Structure and
      molecular virology. In: Zuckerman AJ, Thomas HC. eds.
      Viral Hepatitis, 2nd ed. London: Churchill Livingston;

      19. Alter MJ. Epidemiology of hepatitis C. Hepatology

      20. Akahane Y, Kojima M, Sugai Y. Hepatitis C viral
      infection in spouses of patients with type C chronic
      liver disease. Ann Intern Med 1994;120:748-752.

      21. Reinus JF, Leikin EL, Later HJ, et al. Failure to
      detect vertical transmission of hepatitis C virus. Ann
      Int Med 1992;117:881-886.

      22. Conry-Cantilena C, VanRaden MA, Gibble J, et al.
      Routes of infection, viremia, and liver disease in
      blood donors found to have hepatitis C virus
      infection. N Engl J Med 1996;334:1691-1696.

      23. Alter MJ. Epidemiology of hepatitis C in the west.
      Semin Liver Dis 1995;15:5-14.

      24. Allander T, Gruber A, Naghavi M, et al. Frequent
      patient-to-patient transmission in a hematology ward.
      Lancet 1995;345:603-607.

      25. Esteban JI, Gomez J, Martell M, et al.
      Transmission of hepatitis C virus by a cardiac
      surgeon. N Engl J Med 1996;334:555-560.

      26. Dienstag JL. Non-A, non-B hepatitis. I.
      Recognition, epidemiology, and clinical features.
      Gastroenterol 1983;85:439-462.

      27. McGaughan GW, McGuiness PH, Bishop GA, et al.
      Clinical assessment and incidence of hepatitis C RNA
      in 50 consecutive RIBA-positive volunteer blood
      donors. Med J Aust 1992;157:231-233.

      28. Alter HJ, Purcell RH, Fienstone SM, et al. Non-A,
      non-B hepatitis: a review and interim report of an
      ongoing prospective study. In: Szmuners W, Alter HJ,
      Maynard JE, eds. Viral Hepatitis: 1981 International
      Symposium. Philadelphia, PA: Franklin Institute Press,

      29. Kiyosawa K, Sodeyama T, Tanaka E, et al. Natural
      history of hepatitis C. Intervirology 1994;37:101-107.

      30. Hoofnagle J. Hepatitis C: the clinical spectrum of
      disease. Hepatology 1997;26:15S-20S.

      31. Okuda A. Natural history of chronic hepatitis C
      and hepatocellular carcinoma. In Zuckerman AJ, Thomas
      HC, eds. Viral Hepatitis, 2nd ed. London: Churchill
      Livingstone; 1998:309-318.

      32. Prieto P, Plasp V, Verdu C, et al. Does the
      healthy hepatitis C virus carrier state really exist?
      An analysis using polymerase chain reaction.
      Hepatology 1995;22:413-417.

      33. Mercan I, Sherlock S, McIntyre N, et al. Clinical,
      biochemical and histological features in 102 patients
      with chronic hepatitis C virus infection. Quart J Med

      34. Agnello V, Chung RT, Kaplan LM. A role of
      hepatitis C virus infection in type II
      cryoglobulinemia. N Engl J Med 1992;327:1490-1495.

      35. DeCastro M, Sanchez J, Herrera JF, et al.
      Hepatitis C virus antibodies and liver disease in
      patients with porphyria cutanea tarda. Hepatology
      1992;16:231. [Abstract]

      36. Sulkowski MS. Hepatitis C virus and HIV
      coinfection. CRIA Update 1998;8:15-18.

      37. Watson HG, Zhang LQ, Simmons P, et al. Hepatitis C
      viral load increases with time after HIV infection.
      Int Conf AIDS 1992;July:19-24; B195 (abstract # PoB

      38. Darby SC, Ewart DW, Giagrande PLF, et al.
      Mortality from liver cancer and liver disease in
      hemophiliac men and boys in UK given blood products
      contaminated with hepatitis C. Lancet

      39. Nishioka K, Watanabe J, Furuta S, et al. A high
      prevalence of antibody to the hepatitis C virus with
      hepatocellular carcinoma in Japan. Cancer

      40. Bruix J, Barrera JM, Calvet X, et al. Prevalence
      of antibodies to hepatitis C virus in Spanish patients
      with hepatocellular carcinoma and hepatic cirrhosis.
      Lancet 1989;28:1004-1006.

      41. Bisceglie AM. Hepatitis C and hepatocellular
      carcinoma. NIH Consensus Development Conference:
      Management of Hepatitis C. Program and Abstracts.
      Office of the Director, National Institutes of Health.
      March 24, 1997. National Institutes of Health,
      Bethesda, Maryland.

      42. Zoli M, Magalotti D, Bianchi G, et al. Efficacy of
      a surveillance program for early detection of
      hepatocellular carcinoma. Cancer 1996;78:977-985.

      43. Levine R. Treating histologically mild chronic
      hepatitis C: monotherapy, combination therapy, or
      tincture of time? Ann Intern Med 1998;129:323-326.

      44. Haber MM, West AB, Haber AD, et al. Relationship
      of aminotransferase to liver histological status in
      chronic hepatitis C. AM J Gastroenterology

      45. Bedosa P, Poynard T. An algorithim for the grading
      of activity in chronic hepatitis C. The METAVIR
      Cooperative Study Group. Hepatology 1996;24:289-293.

      46. Poynard T, Bedosa P, Opolon P. Natural history of
      lower fibrosis progression in patients with chronic
      hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and
      DOSVIRC groups. Lancet 1997;349:825-832.

      47. Bader TF. Clinical features of hepatitis C. In:
      Bader TF, ed. Viral Hepatitis, Practical Evaluation
      and Treatment 1st ed. Seattle, WA: Hogrefe & Huber;

      48. Scheuer PJ, Ashrefzadeh P, Sherlock S, et al. The
      pathology of hepatitis C. Hepatology 1992;15:567-571.

      49. Bach N, Thung S, Schnafer F. The histological
      features of chronic hepatitis C and autoimmune chronic
      hepatitis: a comparative analysis. Hepatology

      50. Gonzales-Peralta RP, Lau JYN. Pathogenic
      mechanisms for hepatocellular damage in chronic
      hepatitis C virus infection. Semin Gastro

      51. Lim HL, Nelson DR, Fang JWS. The tumor necrosis
      factor-alpha system in chronic hepatitis C. Hepatology

      52. O'Garra A. Interleukins and the immune system 1.
      Lancet 1989;1:943-946.

      53. Clerici M, Shearer GM. A TH1 to TH2 switch is a
      critical step in the etiology of HIV infection.
      Immunol Today 1993;14:107-111.

      54. Personal communication; July 1999. Patrick Bouic,
      PhD, Dept. of Medical Microbiology, Medical Faculty,
      University of Stellenbosch, Tygerberg 7505, South

      55. Lirussi F, Sanchez B, Pelizzari L, et al. Natural
      killer cells in patients with chronic hepatitis C
      (CHC). Gut 1998;42:A32.

      56. Chemello L, Cavaletto L, Bernardinello E, et al.
      The effect of interferon alfa and ribavirin
      combination therapy in na�ve patients with chronic
      hepatitis C. J Hepatol 1995;23:S8-S12.

      57. Reichard O, Yun Z-B, Sonnerborg A, et al.
      Hepatitis C viral RNA titers in serum prior to, during
      and after oral treatment with ribavirin for chronic
      hepatitis C. J Med Virol 1993;41:99-102.

      58. Di Bisceglie AM, Bacon BR, Kleiner DE, et al.
      Increase in hepatic iron stores following prolonged
      therapy with ribavirin in patients with chronic
      hepatitis C. J Hepatol 1994;21:1109-1112.

      59. Dusheiko G, Main J, Thomas HC, et al. Ribavirin
      treatment for patients with chronic hepatitis C:
      results of a placebo controlled study. J Hepatol

      60. Gane EJ, Su-Kong L, Riordan SM, et al. A
      randomized study comparing ribavirin and interferon
      alfa monotherapy for hepatitis C recurrence after
      liver transplantation. Hepatology 1998;27:1403-1407.

      61. Ning Q, Brown D, Parodo J. Ribavirin inhibits
      procoagulant activity and viral induced macrophage
      production of TNF and IL1, while preserving TH1
      cytokine production and inhibiting TH2 cytokine
      response. Hepatology 1996;24:355A.

      62. Salen G, Ahrens EH, Grundy AM. Metabolism of
      beta-sitosterol in man. J Clin Invest 1970;49:952-967.

      63. Bouic PJD, Etsebeth RW, Liebenberg CF.
      Beta-sitosterol and beta-sitosterol glucoside
      stimulate human peripheral blood lymphocyte
      proliferation: implications for their use as an
      immunomodulatory vitamin combination. Int J
      Immunopharmac 1996;18:693-700.

      64. Weihrach JL, Gardner JM. Sterol content of foods
      of plant origin. J Amer Diet Assoc 1978;73:39-47.

      65. Yamamoto M, Matsui T, Sugiyama K, et al.
      Anti-inflammatory active constituents of Aloe
      arborescens Miller. Agric Biol Chem 1991;55:1627-1629.

      66. Ivorra MD, D'Ocon MP, Paya M, et al.
      Anti-hyperglycemic and insulin releasing effects of
      beta-sitosterol 3-B-D-glucoside and its aglycone
      beta-sitosterol. Arch Int Pharmacodyn Ther

      67. Carbin BE, Larsson B, Lindake O. Treatment of
      benign prostatic hyperplasia with phytosterols. B J
      Urol 1990;66:629-641.

      68. Pegel KH. The importance of sitosterol and
      sitosterolin in human and animal nutrition. S Afr J
      Sci 1997;93:263-268.

      69. Bouic PJD. Sterols/sterolins, nontoxic
      immunomodulators and their role in the control of
      rheumatoid arthritis. Newsletter of the Arthritis
      Trust of America; Summer 1998.

      70. Bouic PJD. Immunomodulation in HIV/AIDS: The
      Tygerberg/Stellenbosch University Experience. AIDS
      Bulletin 1997;6:18-20.

      71. Personal communication; July 1999. Patrick Bouic,
      PhD, Dept. of Medical Microbiology, Medical Faculty,
      University of Stellenbosch, Tygerberg 7505, South

      72. Pinto HC, Baptista A, Camilo ME, et al.
      Nonalcoholic steatohepatitis. Clinicopathological
      comparison with alcoholic hepatitis in ambulatory and
      hospitalized patients. Dig Dis Sci 1996;41:172-179.

      73. Letteron P, Fromenty B, Terris B, et al. Acute and
      chronic hepatitic steatosis lead to in vivo lipid
      peroxidation in mice. J Hepatol 1996;24:200-208.

      74. MacSween RNM. Pathology of viral hepatitis and its
      sequelae. Clin Gastroenterol 1980;9:23-45.

      75. Day CP, James OFW. Hepatic steatosis: innocent
      bystander or guilty party? Hepatology

      76. Reeves HL, Burt AD, Wood S, et al. Hepatic
      stellate cell activation occurs in the absence of
      hepatitis in alcoholic liver disease and correlates
      with the severity of steatosis. J Hepatol

      77. Wenzel G, Kulinski B, Ruhlman C. Alcohol-induced
      toxic hepatitis � a free radical associated disease.
      Lowering fatality by adjuvant antioxidant therapy. Z
      Gesamte Inn Med 1993;48:490-496.

      78. Reizis AR, Malinovskaia VV, Shekhade S, et al.
      Effectiveness of using recombinant interferon alfa2
      (reaferon) combined with antioxidants in children with
      acute hepatitis B. Pediatriia 1992;1:60-64. [Article
      in Russian]

      79. Beloqui O, Prieto J, Suarez M, et al. N-acetyl
      cysteine enhances the response to interferon-alpha in
      chronic hepatitis C: a pilot study. J Interferon Res

      80. Hoglum K, Ventkataramani A, Lyche K, et al. A
      pilot study of the effects of d-alpha tocopherol on
      hepatic stellate cell activation in chronic hepatitis
      C. Gastroenterology 1997;113:1069-1073.

      81. Fujisawa K, Tandon BN. Therapeutic approach to the
      chronic active liver disease: Summary of a satellite
      symposium. In: Nishioka K, Suzuki H, Mishiro S, et al.
      eds. Viral Hepatitis and Liver disease. Tokyo:
      Springer; 1994:662-665.

      82. Hattori M. Metabolism of glycyrrhizin by human
      intestinal flora II. Isolation and characterization of
      human intestinal bacteria capable of metabolizing
      glycyrrhizin and related compounds. Chem Pharm Bull

      83. Nose M, Ito M, Kamimura K, et al. A comparison of
      the anti-hepatotoxic activity between glycyrrhizin and
      glycyrrhetinic acid. Planta Med 1994;60:136-139.

      84. Abe N, Ebina T, Ishida N. Interferon induction by
      glycyrrhizin and glycyrrhetinic acid in mice.
      Microbiol Immunol 1982;26:535-539.

      85. Pompei R, Flore O, Marccialis MA, et al.
      Glycyrrhizic acid inhibits virus growth and
      inactivates virus particles. Nature 1979;281:689-690.

      86. Crance JM, Biziagos E, Passagot J, et al.
      Inhibition of hepatitis A virus replication in vitro
      by antiviral compounds. J Med Virol 1990;31:155-160.

      87. Crance JM, Leveque F, Biziagos E, et al. Studies
      on the mechanism of action of glycyrrhizin against
      hepatitis A virus replication. Antiviral Res

      88. Nagai T, Egashira T, Yamanaka Y, et al.
      Attenuation of dysfunction in the ischemia-reperfusion
      liver by glycyrrhizin. Arch Environ Contam Toxicol

      89. Kimura M, Watanabe H, Abo T. Selective activation
      of extrathymic T cells in the liver by glycyrrhizin.
      Biotherapy 1992;5:167-176.

      90. Suzuki H, Ohta Y, Takino T, et al. The therapeutic
      effects of Stronger Neo Minophagen C for chronic
      hepatitis. Igaku no Ayumi 1977;102:562-568.

      91. Hino K, Miyakawa H, Kondo T, et al. Effects of
      glycyrrhizin therapy on liver histology in chronic
      aggressive hepatitis. In: Shikata T, Purcell RH,
      Uchida T, eds. Viral Hepatitis C, D, and E. Amsterdam:
      Excerpta Medica; 1987:295-303.

      92. Yasuda K, Hino K, Fujioka S, et al. Effects of a
      high dose therapy with Stronger Neo Minophagen C
      (SNMC) on hepatic histography in non-A, non-B chronic
      active hepatitis. In: Shikata T, Purcell RH, Uchida,
      eds. Viral Hepatitis C, D, and E. Amsterdam: Excerpta
      Medica; 1991:205-209.

      93. Hoofnagle JH, Lau D, Conjeervaram H, et al.
      Prolonged therapy of chronic hepatitis C with
      ribavirin. J Viral Hepatitis 1996;3:247-252.

      94. Arase Y, Ikeda K, Murashima N. The long term
      efficacy of glycyrrhizin in chronic hepatitis C
      patients. Cancer 1997;79:1494-1500.

      95. Xianshi S, Huiming C, Lizhuang W, et al. Clinical
      and laboratory observation on the effect of
      glycyrrhizin in acute and chronic viral hepatitis. J
      Tradit Chin Med 1984;4:127-132.

      96. Perissoud D, Weibel I. Protective effect of
      (+)-cyanidanol-3 in acute liver injury induced by
      galactosamine or carbon tetrachloride in the rat.
      Naunyn Schmiedeberg's Arch Pharmacol 1980;312:285-291.

      97. Balant L. Clinical pharmacology of
      (+)-cyanidanol-3: a synopsis with emphasis on
      pharmacokinetics. In: Conn HO, ed. International
      Workshop on (+)-Cyanidanol-3 in Liver Diseases.
      London: The Royal Society of Medicine; 1981:49-54.

      98. Colman C, Morgan MY, Scheur PJ, et al. Treatment
      of alcohol-related liver disease with
      (+)-cyanidanol-3: a randomised double-blind trial. Gut

      99. World MJ, Aps EJ, Shaw GK, Thomson AD.
      (+)-Cyanidanol-3 for alcoholic liver disease: results
      of a six-month clinical trial. Alcohol Alcohol

      100. Piazza M, Guadagnino V, Picciotto G, et al.
      Effect of (+)-cyanidanol-3 in acute HAV, HBV, and
      non-A, non-B viral hepatitis. Hepatology 1983;3:45-49.

      101. Blum AL, Doelle W, Kortum K, et al. Treatment of
      acute viral hepatitis with (+)-cyanidanol-3. Lancet

      102. Di Nola F. (+)-Cyanidanol-3 in acute viral
      hepatitis. Lancet 1980;2:1379-1380.

      103. Piazza M, de Mercator R, Guadagnino V, et al.
      Effect of (+)-cyanidnaol-3 on chronic persistent or
      chronic active hepatitis. In: Conn HO, ed.
      International Workshop on (+)-Cyanidanol 3 in Diseases
      of the Liver. London: The Royal Society of Medicine;

      104. Loginov AS, Dzhalalov KD, Blok IuE, et al.
      Treatment of chronic diseases of the liver with
      catergen. Ter Arkh 1986;58:73-76. [Article in Russian]

      105. Suzuki H, Yamamato S, Hirayama C. Cianidanol
      therapy for Hbe-antigen-positive chronic hepatitis: a
      multicentre, double-blind study. Liver 1986;6:35-44.

      106. Salama A, Mueller-Eckhardt C. Cianidanol and its
      metabolites bind tightly to red cells and are
      responsible for the production of auto- and/or
      drug-dependent antibodies against these cells. Br J
      Haematol 1987;66:263-266.

      107. Gandolfo GM. Hemolytic anemia and
      thrombocytopenia induced by cyanidanol. Acta Haematol

      108. Luper S. A review of plants used in the treatment
      of liver disease: Part 1. Altern Med Rev

      109. Gagliardi B, Fiori GP. Results of a double blind
      study on the effect of silymarin in the treatment of
      acute viral hepatitis, carried out at two medical
      centers. Med Klin 1978;73:1060-1065.

      110. Moscarelli S, Guisti A, Marra F, et al.
      Therapeutic and anti-lipoperoxidant effects of
      silybin-phosphatidylcholine complex in chronic liver
      disease: preliminary results. Curr Ther Res

      111. Vailaii A, Arista I, Sozze E, et al. Randomized
      open study of the dose-effect relationship of a short
      course of IdB1016 in patients with viral or alcoholic
      hepatitis. Fitoterapia 1993;64:219-228.

      112. Mehrotra R, Rawat S, Kulshreshtha DK, et al. In
      vitro studies on the effect of certain natural
      products against hepatitis B virus. Indian J Med Res

      113. Jayaram S, Thyagarajan SP. Inhibition of HBsAg
      secretion from Alexander cell line by Phyllanthus
      amarus. Indian J Pathol Microbiol 1996;39:211-215.

      114. Ott M, Thyagarajan SP, Gupta S. Phyllanthus
      amarus suppresses hepatitis B virus by interrupting
      interactions between HBV enhancer I and cellular
      transcription factors. Eur J Clin Invest

      115. Wang M, Cheng H, Li Y, et al. Herbs of the genus
      Phyllanthus in the treatment of chronic hepatitis B:
      observations with three preparations from different
      geographic sites. J Lab Clin Med 1995;126:350-352.

      116. Thamlikitkul V, Wasuwat S, Kanchanapee P.
      Efficacy of Phyllanthus amarus for eradication of
      hepatitis B virus in chronic carriers. J Med Assoc
      Thai 1991;74:381-385.

      117. Milne A, Hopkirk N, Lucas CR, et al. Failure of
      New Zealand hepatitis B carriers to respond to
      Phyllanthus amarus. N Z Med J 1994;107:243.

      118. Kann M, Gerlich W. Structure and molecular
      virology. In: Zuckerman AJ, Thomas HC, eds. Viral
      Hepatitis. London: Churchill Livingston;1998:77-99.

      119. Thomas HC, Thurz MR. Pathogenesis of chronic
      hepatitis B. In: Zuckerman AJ, Thomas HC, eds. Viral
      Hepatitis. London: Churchill Livingston;1998.

      120. Main J, Thomas HC. Treatment of chronic hepatitis
      B. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis.
      London: Churchill Livingston;1998.

      Do You Yahoo!?
      Yahoo! Photos - Share your holiday photos online!
    Your message has been successfully submitted and would be delivered to recipients shortly.